Selank

Summary

Selank is a synthetic peptide developed in Russia as an anti-anxiety drug. It is a modified version of tuftsin, a naturally occurring peptide involved in immune signaling, re-engineered for stability and brain effects. In Russia it has been used clinically as an anxiolytic, and it is promoted internationally as a calming, non-sedating, non-addictive alternative to benzodiazepines — plus, increasingly, as a "nootropic" for focus and mood. The honest state of the evidence is that there is real human research, but it is thin and hard to verify: a small number of mostly Russian trials, not independently replicated to Western standards, and no approval outside Russia. That makes Selank more evidence-backed than a pure internet supplement, but far from a proven treatment — which is why its claims grade in the middle, not the top.

What people use it for

People use Selank mainly for anxiety — described as a "take the edge off" calm without the sedation, cognitive fog, or dependence associated with benzodiazepines — and for stress resilience. A growing second use is as a nootropic: users take it (usually as a nasal spray) for focus, mental clarity, motivation, and mood, sometimes paired with its sibling peptide Semax. It is also discussed for immune support, reflecting its tuftsin origin. The evidence sections weigh these uses against the (limited) research.

Human evidence

Selank's human evidence is genuine but small, and concentrated in Russian clinical research.

The most-cited study (Zozulia et al., 2008) was a comparative trial in patients with generalized anxiety disorder (GAD) and neurasthenia, testing Selank against the benzodiazepine medazepam. The authors reported that Selank produced anxiolytic activity broadly similar to the benzodiazepine on standard anxiety scales (Hamilton, Zung, Clinical Global Impression), with an additional "anti-asthenic" (anti-fatigue) effect and changes in enkephalin markers that tracked with anxiety reduction — and without the benzodiazepine's typical drawbacks. Taken at face value, that is a positive human result for anxiety.

The important caveats are about strength and verifiability, and they are why this brief grades the anxiety claim B rather than higher: the trial was small (on the order of 60 patients), used an active comparator rather than placebo, came from a single research group, was published in Russian, and has not been independently replicated in large, Western-standard, placebo-controlled trials. For the nootropic/cognitive claims specifically, the human evidence is even thinner — much of the support is preclinical or anecdotal rather than from controlled cognition trials. So Selank sits in an unusual spot: not unstudied, but not robustly proven either.

Animal / preclinical evidence

The preclinical picture is more developed than the clinical one and gives the anxiety claim some mechanistic plausibility. In animal and molecular studies, Selank influences GABAergic neurotransmission (the brain's main inhibitory, calming system — the same broad system benzodiazepines act on, though Selank works differently), affects expression of genes tied to that system (Volkova et al.), and has been reported to modulate monoamine systems, enkephalin metabolism, and BDNF (a neurotrophic factor linked to mood and learning). Its tuftsin lineage also gives it immune-modulating activity in lab models. This is a coherent mechanistic story consistent with an anxiolytic/nootropic effect — but, as always, plausible mechanism plus small human trials is a reason to take it seriously, not a substitute for the large controlled trials that haven't been done.

Anecdotal / community reports

Low-confidence. These are community reports, not evidence. Not medical guidance.

Selank has an enthusiastic online following. Users commonly report a gentle, non-sedating reduction in anxiety, smoother mood, better stress tolerance, and improved focus, usually from an intranasal spray and often within a short time of dosing. Many specifically contrast it favorably with benzodiazepines (no grogginess, no dependence). These reports are consistent with the limited trial data, but they are uncontrolled, subject to placebo and expectancy effects, and based on gray-market product of uncertain quality — so they reinforce rather than establish the case.

Doses used in published studies

Context only — not a recommendation. PeptideIQ Base does not provide dosing advice.

Selank has been used clinically in Russia primarily as an intranasal preparation, but precise, well-documented clinical dosing is not reliably available in accessible English-language sources. Rather than publish a dose we cannot tie to a verifiable study, this brief lists no study-dose figures for Selank. The absence here is deliberate — it reflects the limits of the verifiable record, not an oversight.

Safety & side effects

In the available Russian studies, Selank has been described as well tolerated, with a notable absence of the sedation, cognitive impairment, withdrawal, and dependence that limit benzodiazepines — a major part of its appeal. However, this favorable profile comes from small, short-term studies, mostly from one research tradition, so the safety database is limited and long-term human safety is not well characterized. There is no FDA review of its safety, and the product sold outside Russia is unapproved, gray-market material of unverified identity, purity, and concentration — which adds contamination and mislabeling risks independent of the molecule itself. "Few reported side effects in small studies" is encouraging but is not the same as established long-term safety.

Regulatory / legal status

Selank is not FDA-approved, and it is not approved by the EMA or other Western regulators. It was developed in Russia and has been registered and used clinically there as an anxiolytic, typically in an intranasal form. Outside Russia it has no marketing authorization for any use, and it is sold internationally as a gray-market / "research only" peptide; using it for anxiety, focus, or mood in the US is unapproved. Regulatory and legal status varies by country and can change; this is not legal or medical advice.

Podcast / media mentions

Selank appears across nootropic, biohacking, and anxiety-focused content as a "Russian anti-anxiety peptide" that calms without the downsides of benzodiazepines. That framing is partly earned and partly overstated. Earned: unlike many internet supplements, Selank has actual clinical research behind it, including a trial that compared it head-to-head with a benzodiazepine, plus a plausible GABAergic mechanism. Overstated: that evidence is small, single-region, and unreplicated to Western standards, the nootropic claims in particular rest more on anecdote and mechanism than on controlled trials, and the product people buy is unapproved gray-market material. Where coverage presents Selank as a promising but under-proven peptide with mostly Russian evidence, it squares with the record; where it implies a clinically validated, side-effect-free anxiety cure, it runs ahead of the data. The critique is of the framing, not of the research.